Intense Pulsed Light Therapy in Meibomian Gland Dysfunction
NCT ID: NCT04904874
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2020-12-01
2021-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction
NCT03518398
Treatment of Meibomian Gland Dysfunction
NCT01683318
Intense Regulated Pulse Light Therapy in Dry Eye Disease
NCT05553561
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
NCT03396913
Intense Pulsed Light in Meibomian Gland Dysfunction
NCT05089591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
flourescein staining, miboscore
intense pulsed light
treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intense pulsed light
treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The diagnosis of obstructive MGD based on ocular symptoms, plugged gland orifices, vascularity and irregularity of lid margins, and reduced meibum expression (meibum grade of .1, where grade 0 = clear meibum easily expressed, grade 1 = cloudy meibum expressed with mild pressure, grade 2 = cloudy meibum expressed with more than moderate pressure, and grade 3 = meibum could not be expressed even with strong pressure).
* failure of at least 3 types of conventional MGD therapy to improve symptoms or objective findings for at least 1 year before study treatment
Exclusion Criteria
* active ocular infection or ocular inflammatory disease.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dar Al Shifa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
magda torky
catract and refractie surgery specilaist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dar alshif hospital
Kuwait City, , Kuwait
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
magda torky
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02282021065726
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.